WO2010003003A1 - Implants including fractal structures - Google Patents

Implants including fractal structures Download PDF

Info

Publication number
WO2010003003A1
WO2010003003A1 PCT/US2009/049422 US2009049422W WO2010003003A1 WO 2010003003 A1 WO2010003003 A1 WO 2010003003A1 US 2009049422 W US2009049422 W US 2009049422W WO 2010003003 A1 WO2010003003 A1 WO 2010003003A1
Authority
WO
WIPO (PCT)
Prior art keywords
endoprosthesis
bioerodable
stent
fractal structure
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/049422
Other languages
French (fr)
Inventor
Liliana Atanasoska
Tom Holman
James Q. Feng
Robert W. Warner
Afsar Ali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Scimed Inc
Original Assignee
Scimed Life Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scimed Life Systems Inc filed Critical Scimed Life Systems Inc
Publication of WO2010003003A1 publication Critical patent/WO2010003003A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth

Definitions

  • This invention relates to implants, and more particularly to stents.
  • the body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis.
  • An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprostheses include stents, covered stents, and stent-grafts.
  • Endoprostheses can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen.
  • the expansion mechanism can include forcing the endoprosthesis to expand radially.
  • the expansion mechanism can include the catheter carrying a balloon, which carries a balloon-expandable endoprosthesis. The balloon can be inflated to deform and to fix the expanded endoprosthesis at a predetermined position in contact with the lumen wall. The balloon can then be deflated, and the catheter withdrawn.
  • the endoprosthesis is formed of an elastic material that can be reversibly compacted and expanded, e.g., elastically or through a material phase transition.
  • the endoprosthesis is restrained in a compacted condition.
  • the restraint is removed, for example, by retracting a restraining device such as an outer sheath, enabling the endoprosthesis to self-expand by its own internal elastic restoring force.
  • An endoprosthesis includes a member having a surface that includes a fractal structure.
  • a fractal structure includes a rough or fragmented geometric shape that can be subdivided in parts, each part being (at least approximately) a reduced-size copy of the rough or fragmented geometric shape.
  • the term "fractal structure” means a structure that includes similar structures at magnification factors of 1 ,000 and 10,000.
  • the fractal structure can have a surface area greater than 5 times the surface area of a smooth surface having the same dimensions.
  • the fractal structure can include a cauliflower-like structure.
  • the fractal structure can include nanopits.
  • the member can include a bioerodable material (e.g., a bioerodable metal or a bioerodable polymer).
  • the bioerodable metal can be magnesium, zinc, iron, or an alloy thereof.
  • the bioerodable polymer can be polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly-L-lactide, poly-D-lactide, polyglycolide, poly(alpha-hydroxy acid), or combinations thereof.
  • the member can include a non-biodegradable metal (e.g., stainless steels, platinum enhanced stainless steels, cobalt-chromium alloys, nickel titanium alloys, and combinations thereof).
  • a non-biodegradable metal e.g., stainless steels, platinum enhanced stainless steels, cobalt-chromium alloys, nickel titanium alloys, and combinations thereof.
  • the surface that includes the fractal structure can be an outermost surface of the endoprosthesis.
  • the endoprosthesis can further include a second material overlying the fractal structure.
  • the second material can be a tie layer, a biocompatible coating, a drug-eluting layer, a radiopaque metal or alloy, or a combination thereof.
  • the endoprosthesis may be provided in the form of a stent.
  • the endoprosthesis can be a bioerodable stent including a bioerodable member having a surface having a fractal structure, where the surface includes iron or an alloy thereof.
  • an implant that includes a bioerodable material having a surface that includes a fractal structure.
  • the implant can be in the form of a stent, a cochlear implant, a bone screw, a neuron aneurysm coil, a septal defect plug, a venous valve support structure, a pacing lead, a spinal implant support structure, a hip replacement joint, or a inter uterine implant.
  • FIG. 1. illustrates an exemplary stent.
  • a stent 20 can have the form of a tubular member defined by a plurality of bands 22 and a plurality of connectors 24 that extend between and connect adjacent bands.
  • bands 22 can expand from an initial, small diameter compressed state to a larger diameter to contact the stent 20 against a wall of a vessel, thereby maintaining the patency of the vessel.
  • Connectors 24 can provide stent 20 with flexibility and conformability that allow the stent to adapt to the contours of the vessel.
  • the stent 20 can include a surface that has a fractal structure, as described in the Summary, above. By providing a fractal structure to the surface of a stent, the surface area of the stent can be increased.
  • the fractal structure can have a surface area greater than 5 times the surface area of a smooth surface having the same dimensions.
  • the fractal structure on the surface of stent 20 can include a number of fractal structures.
  • the fractal structure can include a cauliflower- like structure at magnification factors of at least 1,000 and 10,000.
  • the fractal structure can include nanopits.
  • each nanopit can include nanopit walls including smaller nanopits having a similar structure to the larger nanopit, but on a smaller scale.
  • the fractal structure geometry can be tailored to almost any shape/structure that is desired. It can be made to match the stent geometry or it can be made not to match.
  • Stent 20 can, in some embodiments, include a bioerodable material (e.g., a bioerodable metal or a bioerodable polymer).
  • a bioerodable metal can include magnesium, zinc, iron, or an alloy thereof.
  • the bioerodable material can be a metallic iron or an alloy thereof (e.g., Fe-35Mn).
  • an iron stent having an outermost surface having a fractal structure could allow for a faster erosion rate.
  • the bioerodable material can also be a bioerodable polymer such as polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly-L-lactide, poly-D-lactide, polyglycolide, poly(alpha-hydroxy acid), or combinations thereof.
  • a bioerodable polymer such as polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly-L-lactide, poly-D-lactide, polyglycolide, poly(alpha-hydroxy acid), or combinations thereof.
  • Stent 20 can, in some embodiments, include non-biodegradable materials, such as stainless steels, platinum enhanced stainless steels, cobalt-chromium alloys, nickel titanium alloys, or a combination thereof.
  • stent 20 can include bioerodable and non-bioerodable portions.
  • Stent 20 can include a uniform distribution of fractal structures.
  • an iron stent body can include a uniform distribution of fractal structures over its entire surface.
  • stent 20 can include the fractal structure on only an abdominal surface.
  • Stent 20 can, in some embodiments include regions of preferred erosion.
  • the stent 20 can include select bands 22 or connectors 24, or portions thereof, that include the fractal structure, while the remaining surfaces are smooth.
  • every surface of the stent body can include the fractal structures, but select bands and/or connectors can include an outer coating to delay the erosion of those select bands and/or connectors.
  • Stent 20 can, in some embodiments, include a layer of a second material overlying the surface.
  • the layer of second material can overlie at least a portion of the fractal structure.
  • the layer of the second material can be, for example, a tie layer, a biocompatible outer coating, a radiopaque metal or alloy, and/or a drug-eluting layer.
  • Drug eluting layers can be made of biodegradable polymer coatings such as polyesters, polyamide, polyanhidrides, polysaccharides, examples such as PLGA, PLA, Chitosan. Also biological polymers based on rproteins, peptides and amino acids are an option. Besides polymers one can use biodegradable ceramics based on phosphates.
  • a stainless steel stent surface can include a fractal structure and include a layer of a drug-eluting polymer coating over the fractal structure. The presence of the fractal structure could improve the adhesion of a drug-eluting coating to a stainless steel stent surface.
  • a fractal structure can be formed on a surface of a stent by a number of suitable deposition or patterning treatments, such as plasma enhanced physical vapor deposition, laser etching, and/or chemical etching.
  • suitable deposition or patterning treatments such as plasma enhanced physical vapor deposition, laser etching, and/or chemical etching.
  • plasma enhanced physical vapor deposition argon ions from a plasma are accelerated in a high vacuum apparatus by an outside electrical field towards a cathode made of the coating material (e.g., Iron).
  • a cathode made of the coating material e.g., Iron
  • Single cathode atoms e.g., iron atoms
  • a fractal structure can be obtained.
  • a fractal surface produced by a diffusion limited plasma- enhanced physical vapor deposition process can have a cauliflower- like appearance at a variety of magnification factors (e.g., at magnification factors between 1,000 and 10,000).
  • magnification factors e.g., at magnification factors between 1,000 and 10,000.
  • An example of a fractal structure having a cauliflower- like structure at both magnification factors of 1,000 and 16,000 can be found in Figures 3 and 4 of Schaldach et al, Journal of Material Sciences, Materials in Medicine, 6 (1995) 844.
  • Chemical etching can also be used to produce a fractal structure, e.g., a fractal structure of nanopits.
  • An example of a chemically etched fractal structure of nanopits is shown in Figure 5B of Yi et al, Surface Science 600, 2006, 4613.
  • Stents 10 can be of any desired shape and size (e.g., superficial femoral artery stents, coronary stents, aortic stents, peripheral vascular stents, gastrointestinal stents, urology stents, and neurology stents).
  • the stent can have a diameter of between, for example, 1 mm to 46 mm.
  • a coronary stent can have an expanded diameter of from 2 mm to 6 mm.
  • a peripheral stent can have an expanded diameter of from 5 mm to 24 mm.
  • a gastrointestinal and/or urology stent can have an expanded diameter of from 6 mm to about 30 mm.
  • a neurology stent can have an expanded diameter of from about 1 mm to about 12 mm.
  • An abdominal aortic aneurysm (AAA) stent and a thoracic aortic aneurysm (TAA) stent can have a diameter from about 20 mm to about 46 mm.
  • a stent in use, can be used, e.g., delivered and expanded, using a catheter delivery system.
  • catheter systems are described in, for example, Wang U.S.
  • stents can also be a part of a covered stent or a stent- graft.
  • a stent can include and/or be attached to a biocompatible, non-porous or semi-porous polymer matrix made of polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene, urethane, or polypropylene.
  • PTFE polytetrafluoroethylene
  • stents can also include a releasable therapeutic agent, drug, or a pharmaceutically active compound, such as described in U.S. Patent No. 5,674,242, U.S.S.N. 09/895,415, filed July 2, 2001, and U.S.S.N. 10/232,265, filed August 30, 2002.
  • the therapeutic agents, drugs, or pharmaceutically active compounds can include, for example, anti-thrombogenic agents, antioxidants, antiinflammatory agents, anesthetic agents, anti-coagulants, and antibiotics.
  • stents can be formed by fabricating a wire including a fractal structure, and knitting and/or weaving the wire into a tubular member.
  • medical implants other than stents include a fractal structure.
  • Such medical implants can include cochlear implants,septal defect device plugs, AAA graph attachment stents, bone screws, Neuro aneurysm coils, venous valve support structures, heart valve support structure, placing leads, spinal implant support cages, hip replacement joints, inter uterine implants (e.g., for birth control).
  • These medical implants can be formed of a bioerodable metal.
  • the bioerodable metal can be magnesium, iron, zinc, or an alloy thereof.
  • the bioerodable metal can be a metallic iron or alloy thereof.
  • a medical implant could include an iron portion having an outermost surface having a fractal structure.
  • polymeric stents can also include a fractal structure to accelerate the degradation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)

Abstract

An endoprosthesis includes a member having a surface that includes a fractal structure.

Description

Implants Including Fractal Structures
TECHNICAL FIELD
This invention relates to implants, and more particularly to stents.
BACKGROUND
The body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis. An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprostheses include stents, covered stents, and stent-grafts.
Endoprostheses can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen. The expansion mechanism can include forcing the endoprosthesis to expand radially. For example, the expansion mechanism can include the catheter carrying a balloon, which carries a balloon-expandable endoprosthesis. The balloon can be inflated to deform and to fix the expanded endoprosthesis at a predetermined position in contact with the lumen wall. The balloon can then be deflated, and the catheter withdrawn.
In another delivery technique, the endoprosthesis is formed of an elastic material that can be reversibly compacted and expanded, e.g., elastically or through a material phase transition. During introduction into the body, the endoprosthesis is restrained in a compacted condition. Upon reaching the desired implantation site, the restraint is removed, for example, by retracting a restraining device such as an outer sheath, enabling the endoprosthesis to self-expand by its own internal elastic restoring force.
SUMMARY
An endoprosthesis is described that includes a member having a surface that includes a fractal structure. A fractal structure includes a rough or fragmented geometric shape that can be subdivided in parts, each part being (at least approximately) a reduced-size copy of the rough or fragmented geometric shape. As used herein, the term "fractal structure" means a structure that includes similar structures at magnification factors of 1 ,000 and 10,000. In some embodiments, the fractal structure can have a surface area greater than 5 times the surface area of a smooth surface having the same dimensions. In some embodiments, the fractal structure can include a cauliflower-like structure. In some embodiments, the fractal structure can include nanopits.
In some embodiments, the member can include a bioerodable material (e.g., a bioerodable metal or a bioerodable polymer). The bioerodable metal can be magnesium, zinc, iron, or an alloy thereof. The bioerodable polymer can be polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly-L-lactide, poly-D-lactide, polyglycolide, poly(alpha-hydroxy acid), or combinations thereof.
In some embodiments, the member can include a non-biodegradable metal (e.g., stainless steels, platinum enhanced stainless steels, cobalt-chromium alloys, nickel titanium alloys, and combinations thereof).
In some embodiments, the surface that includes the fractal structure can be an outermost surface of the endoprosthesis. In other embodiments, the endoprosthesis can further include a second material overlying the fractal structure. For example, the second material can be a tie layer, a biocompatible coating, a drug-eluting layer, a radiopaque metal or alloy, or a combination thereof.
The endoprosthesis may be provided in the form of a stent. For example, the endoprosthesis can be a bioerodable stent including a bioerodable member having a surface having a fractal structure, where the surface includes iron or an alloy thereof.
An implant is also described that includes a bioerodable material having a surface that includes a fractal structure. For example, the implant can be in the form of a stent, a cochlear implant, a bone screw, a neuron aneurysm coil, a septal defect plug, a venous valve support structure, a pacing lead, a spinal implant support structure, a hip replacement joint, or a inter uterine implant. The details of one or more embodiments are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.
DESCRIPTION OF DRAWINGS FIG. 1. illustrates an exemplary stent.
Like reference symbols in the various drawings indicate like elements.
DETAILED DESCRIPTION
Referring to FIG. 1 , a stent 20 can have the form of a tubular member defined by a plurality of bands 22 and a plurality of connectors 24 that extend between and connect adjacent bands. During use, bands 22 can expand from an initial, small diameter compressed state to a larger diameter to contact the stent 20 against a wall of a vessel, thereby maintaining the patency of the vessel. Connectors 24 can provide stent 20 with flexibility and conformability that allow the stent to adapt to the contours of the vessel. The stent 20 can include a surface that has a fractal structure, as described in the Summary, above. By providing a fractal structure to the surface of a stent, the surface area of the stent can be increased. In some embodiments, the fractal structure can have a surface area greater than 5 times the surface area of a smooth surface having the same dimensions. The fractal structure on the surface of stent 20 can include a number of fractal structures. For example, the fractal structure can include a cauliflower- like structure at magnification factors of at least 1,000 and 10,000. In some embodiments, the fractal structure can include nanopits. For example, each nanopit can include nanopit walls including smaller nanopits having a similar structure to the larger nanopit, but on a smaller scale. The fractal structure geometry can be tailored to almost any shape/structure that is desired. It can be made to match the stent geometry or it can be made not to match.
Stent 20 can, in some embodiments, include a bioerodable material (e.g., a bioerodable metal or a bioerodable polymer). A bioerodable metal can include magnesium, zinc, iron, or an alloy thereof. In some embodiments, the bioerodable material can be a metallic iron or an alloy thereof (e.g., Fe-35Mn). For example, an iron stent having an outermost surface having a fractal structure could allow for a faster erosion rate. The bioerodable material can also be a bioerodable polymer such as polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly-L-lactide, poly-D-lactide, polyglycolide, poly(alpha-hydroxy acid), or combinations thereof.
Stent 20 can, in some embodiments, include non-biodegradable materials, such as stainless steels, platinum enhanced stainless steels, cobalt-chromium alloys, nickel titanium alloys, or a combination thereof. In some embodiments, stent 20 can include bioerodable and non-bioerodable portions. Stent 20 can include a uniform distribution of fractal structures. For example, an iron stent body can include a uniform distribution of fractal structures over its entire surface. In other embodiments, stent 20 can include the fractal structure on only an abdominal surface.
Stent 20 can, in some embodiments include regions of preferred erosion. For example, the stent 20 can include select bands 22 or connectors 24, or portions thereof, that include the fractal structure, while the remaining surfaces are smooth. In other embodiments, every surface of the stent body can include the fractal structures, but select bands and/or connectors can include an outer coating to delay the erosion of those select bands and/or connectors. Stent 20 can, in some embodiments, include a layer of a second material overlying the surface. The layer of second material can overlie at least a portion of the fractal structure. The layer of the second material can be, for example, a tie layer, a biocompatible outer coating, a radiopaque metal or alloy, and/or a drug-eluting layer. Drug eluting layers can be made of biodegradable polymer coatings such as polyesters, polyamide, polyanhidrides, polysaccharides, examples such as PLGA, PLA, Chitosan. Also biological polymers based on rproteins, peptides and amino acids are an option. Besides polymers one can use biodegradable ceramics based on phosphates. For example, a stainless steel stent surface can include a fractal structure and include a layer of a drug-eluting polymer coating over the fractal structure. The presence of the fractal structure could improve the adhesion of a drug-eluting coating to a stainless steel stent surface.
A fractal structure can be formed on a surface of a stent by a number of suitable deposition or patterning treatments, such as plasma enhanced physical vapor deposition, laser etching, and/or chemical etching. By using these processes in a way that reiterates the basic surface structure, a fractal structure can be produced. For example, in plasma-enhanced physical vapor deposition, argon ions from a plasma are accelerated in a high vacuum apparatus by an outside electrical field towards a cathode made of the coating material (e.g., Iron). Single cathode atoms (e.g., iron atoms) can then be sputtered away by the incident argon ions and be deposited on the surface of a stent. By limiting diffusion during the plasma-enhanced physical vapor deposition process, a fractal structure can be obtained.
For example, a fractal surface produced by a diffusion limited plasma- enhanced physical vapor deposition process can have a cauliflower- like appearance at a variety of magnification factors (e.g., at magnification factors between 1,000 and 10,000). An example of a fractal structure having a cauliflower- like structure at both magnification factors of 1,000 and 16,000 can be found in Figures 3 and 4 of Schaldach et al, Journal of Material Sciences, Materials in Medicine, 6 (1995) 844. Chemical etching can also be used to produce a fractal structure, e.g., a fractal structure of nanopits. An example of a chemically etched fractal structure of nanopits is shown in Figure 5B of Yi et al, Surface Science 600, 2006, 4613.
Stents 10 can be of any desired shape and size (e.g., superficial femoral artery stents, coronary stents, aortic stents, peripheral vascular stents, gastrointestinal stents, urology stents, and neurology stents). Depending on the application, the stent can have a diameter of between, for example, 1 mm to 46 mm. In certain embodiments, a coronary stent can have an expanded diameter of from 2 mm to 6 mm. In some embodiments, a peripheral stent can have an expanded diameter of from 5 mm to 24 mm. In certain embodiments, a gastrointestinal and/or urology stent can have an expanded diameter of from 6 mm to about 30 mm. In some embodiments, a neurology stent can have an expanded diameter of from about 1 mm to about 12 mm. An abdominal aortic aneurysm (AAA) stent and a thoracic aortic aneurysm (TAA) stent can have a diameter from about 20 mm to about 46 mm.
In use, a stent can be used, e.g., delivered and expanded, using a catheter delivery system. Catheter systems are described in, for example, Wang U.S.
5,195,969, Hamlin U.S. 5,270,086, and Raeder-Devens, U.S. 6,726,712. Stents and stent delivery are also exemplified by the Sentinol ® system, available from Boston Scientific Scimed, Maple Grove, MN. In some embodiments, stents can also be a part of a covered stent or a stent- graft. In other embodiments, a stent can include and/or be attached to a biocompatible, non-porous or semi-porous polymer matrix made of polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene, urethane, or polypropylene.
In some embodiments, stents can also include a releasable therapeutic agent, drug, or a pharmaceutically active compound, such as described in U.S. Patent No. 5,674,242, U.S.S.N. 09/895,415, filed July 2, 2001, and U.S.S.N. 10/232,265, filed August 30, 2002. The therapeutic agents, drugs, or pharmaceutically active compounds can include, for example, anti-thrombogenic agents, antioxidants, antiinflammatory agents, anesthetic agents, anti-coagulants, and antibiotics.
In some embodiments, stents can be formed by fabricating a wire including a fractal structure, and knitting and/or weaving the wire into a tubular member. In some embodiments, medical implants other than stents include a fractal structure. Such medical implants can include cochlear implants,septal defect device plugs, AAA graph attachment stents, bone screws, Neuro aneurysm coils, venous valve support structures, heart valve support structure, placing leads, spinal implant support cages, hip replacement joints, inter uterine implants (e.g., for birth control). These medical implants can be formed of a bioerodable metal. The bioerodable metal can be magnesium, iron, zinc, or an alloy thereof. In some embodiments, the bioerodable metal can be a metallic iron or alloy thereof. For example, a medical implant could include an iron portion having an outermost surface having a fractal structure.
Furthermore, polymeric stents can also include a fractal structure to accelerate the degradation. All publications, references, applications, and patents referred to herein are incorporated by reference in their entirety.
Other embodiments are within the claims.

Claims

WHAT IS CLAIMED IS:
1. An endoprosthesis comprising a member having a surface that includes a fractal structure.
2. The endoprosthesis of claim 1, wherein the member comprises a bioerodable material.
3. The endoprosthesis of claim 1, wherein the member comprises a bioerodable metal.
4. The endoprosthesis of claim 3, wherein the bioerodable metal comprises magnesium, zinc, iron, or an alloy thereof.
5. The endoprosthesis of claim 3, wherein the member comprises iron or an alloy thereof.
6. The endoprosthesis of claim 1, wherein the member comprises a bioerodable polymer.
7. The endoprosthesis of claim 6, wherein the bioerodable polymer is selected from the group consisting of polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly-L-lactide, poly-D-lactide, polyglycolide, poly(alpha-hydroxy acid), and combinations thereof.
8. The endoprosthesis of claim 1 , wherein the member comprises a non- biodegradable metal selected from the group consisting of stainless steels, platinum enhanced stainless steels, cobalt-chromium alloys, nickel titanium alloys, and combinations thereof.
9. The endoprosthesis of claim 1, wherein the surface is an outermost surface of the endoprosthesis.
10. The endoprosthesis of claim 1, further comprising a second material overlying the surface.
11. The endoprosthesis of claim 10, wherein the second material is selected from the group consisting of a tie layer, a biocompatible coating, a drug-eluting layer, a radiopaque metal or alloy, and combinations thereof.
12. The endoprosthesis of claim 11, wherein the second material is a drug-eluting layer.
13. The endoprosthesis of claim 1, wherein the fractal structure comprises a surface area that is greater than 5 times the surface area of a smooth surface having the same dimensions.
14. The endoprosthesis of claim 1, wherein the fractal structure comprises a cauliflower-like structure.
15. The endoprosthesis of claim 1, wherein the fractal structure comprises nanopits.
16. The endoprosthesis of claim 1, wherein the endoprosthesis is a stent.
17. An implant comprising: a bioerodable material having a surface that includes a fractal structure.
18. The implant of claim 17, wherein the bioerodable material comprises iron or an alloy thereof.
19. The implant of claim 17, wherein the fractal structure comprises a surface area that is greater than 5 times the surface area of a smooth surface having the same dimensions.
20. The implant of claim 17, wherein the fractal structure comprises a cauliflower-like structure.
21. The implant of claim 17, wherein the fractal structure comprises nanopits.
22. The implant of claim 17, wherein the implant is selected from the group consisting of stents, cochlear implants, bone screws, neuron aneurism coils, septal defect plugs, venous valve support structures, pacing leads, spinal implant support structures, hip replacement joints, and inter uterine implants.
23. The implant of claim 17, wherein the implant is a stent.
24. Abioerodable stent comprising: a bioerodable member that includes a surface having a fractal structure, the surface comprising iron or an alloy thereof.
25. The bioerodable stent of claim 24, wherein the fractal structure comprises a surface area that is greater than 5 times the surface area of a smooth surface having the same dimensions.
26. The bioerodable stent of claim 24, wherein the fractal structure comprises cauliflower-like structure.
27. The bioerodable stent of claim 24, wherein the fractal structure comprises nanopits.
28. The bioerodable stent of claim 24, wherein the surface is an outermost surface of the stent.
PCT/US2009/049422 2008-07-02 2009-07-01 Implants including fractal structures Ceased WO2010003003A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/166,507 US20100004733A1 (en) 2008-07-02 2008-07-02 Implants Including Fractal Structures
US12/166,507 2008-07-02

Publications (1)

Publication Number Publication Date
WO2010003003A1 true WO2010003003A1 (en) 2010-01-07

Family

ID=40934169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/049422 Ceased WO2010003003A1 (en) 2008-07-02 2009-07-01 Implants including fractal structures

Country Status (2)

Country Link
US (1) US20100004733A1 (en)
WO (1) WO2010003003A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522220B2 (en) 2013-10-29 2016-12-20 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses
US9603728B2 (en) 2013-02-15 2017-03-28 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses
US10346512B2 (en) 2011-03-01 2019-07-09 Applaud, Llc Personalized memory compilation for members of a group and collaborative method to build a memory compilation
US10589005B2 (en) 2015-03-11 2020-03-17 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081704A1 (en) 1998-02-13 2004-04-29 Centerpulse Biologics Inc. Implantable putty material
US7250058B1 (en) 2000-03-24 2007-07-31 Abbott Cardiovascular Systems Inc. Radiopaque intraluminal stent
US20020114795A1 (en) * 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
DE102006038232A1 (en) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Endoprosthesis and method for producing such
US7718616B2 (en) * 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US10022164B2 (en) 2008-06-11 2018-07-17 Eventions, Llc Orthopedic fastener device
US20110218617A1 (en) * 2010-03-02 2011-09-08 Endologix, Inc. Endoluminal vascular prosthesis
AU2011311255B2 (en) 2010-04-28 2015-10-08 Sorrento Therapeutics, Inc. Method for increasing permeability of an epithelial barrier
RU2570280C2 (en) 2010-04-28 2015-12-10 Кимберли-Кларк Ворлдвайд, Инк. Composite matrix of microneedles, containing nanostructures on surface
CN102985131B (en) 2010-04-28 2016-06-29 金伯利-克拉克环球有限公司 For delivering the medical treatment device of siRNA
CA2797204C (en) 2010-04-28 2018-06-12 Kimberly-Clark Worldwide, Inc. Device for delivery of rheumatoid arthritis medication
WO2011163596A1 (en) 2010-06-25 2011-12-29 Fort Wayne Metals Research Products Corporation Biodegradable composite wire for medical devices
US8613938B2 (en) 2010-11-15 2013-12-24 Zimmer Orthobiologics, Inc. Bone void fillers
US9566147B2 (en) 2010-11-17 2017-02-14 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys containing one or more platinum group metals, refractory metals, or combinations thereof
US11298251B2 (en) 2010-11-17 2022-04-12 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys with primarily single-phase supersaturated tungsten content
US9724494B2 (en) 2011-06-29 2017-08-08 Abbott Cardiovascular Systems, Inc. Guide wire device including a solderable linear elastic nickel-titanium distal end section and methods of preparation therefor
US20170246439A9 (en) 2011-10-27 2017-08-31 Kimberly-Clark Worldwide, Inc. Increased Bioavailability of Transdermally Delivered Agents
ES2374382B2 (en) * 2011-10-27 2012-12-05 Javier Gallastegui Goiburu STENT
BR112014009713A2 (en) 2011-10-27 2017-04-18 Kimberly Clark Co transdermal administration of high viscosity bioactive agents
JP6535464B2 (en) * 2011-10-27 2019-06-26 ソレント・セラピューティクス・インコーポレイテッド Implantable device for delivery of bioactive agents
WO2015137911A1 (en) * 2014-03-10 2015-09-17 Eventions, Llc Orthopedic fastener device
CN104998342A (en) * 2015-07-22 2015-10-28 严聪颖 Medicine-carrying slow release apparatus for uterus, and implantation method thereof
CN105013072B (en) * 2015-07-24 2018-08-31 严聪颖 Band medicine delayed release device for uterus
EP4226956A1 (en) 2018-11-02 2023-08-16 Boston Scientific Scimed, Inc. Biodegradable stent
US11925570B2 (en) 2018-12-19 2024-03-12 Boston Scientific Scimed, Inc. Stent including anti-migration capabilities
US11058564B2 (en) * 2019-02-27 2021-07-13 Vactronix Scientific Llc Stent and method of making same
US12151049B2 (en) 2019-10-14 2024-11-26 Abbott Cardiovascular Systems, Inc. Methods for manufacturing radiopaque intraluminal stents comprising cobalt-based alloys with supersaturated tungsten content

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309414B1 (en) * 1997-11-04 2001-10-30 Sorin Biomedica Cardio S.P.A. Angioplasty stents
US20030100815A1 (en) * 2001-11-27 2003-05-29 Pearl Technology Holdings, Llc In-stent restenosis detection device
US20060271192A1 (en) * 2005-03-04 2006-11-30 Olsen Raymond E Self Fixing Assembled Bone-Tendon-Bone Graft

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868578A (en) * 1972-10-02 1975-02-25 Canadian Patents Dev Method and apparatus for electroanalysis
US4308868A (en) * 1980-05-27 1982-01-05 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Implantable electrical device
DE3682734D1 (en) * 1985-08-23 1992-01-16 Kanegafuchi Chemical Ind ARTIFICIAL VESSEL.
CH670760A5 (en) * 1986-06-02 1989-07-14 Sulzer Ag
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5091024A (en) * 1989-07-13 1992-02-25 Carpenter Technology Corporation Corrosion resistant, magnetic alloy article
DE4104359A1 (en) * 1991-02-13 1992-08-20 Implex Gmbh CHARGING SYSTEM FOR IMPLANTABLE HOERHILFEN AND TINNITUS MASKERS
US5591224A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Bioelastomeric stent
GEP20002074B (en) * 1992-05-19 2000-05-10 Westaim Tech Inc Ca Modified Material and Method for its Production
CA2074318A1 (en) * 1992-07-22 1994-01-23 Morteza Shirkhanzadeh Prosthetic implant with self-generated current for early fixation in skeletal bone
US5380298A (en) * 1993-04-07 1995-01-10 The United States Of America As Represented By The Secretary Of The Navy Medical device with infection preventing feature
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US6185457B1 (en) * 1994-05-31 2001-02-06 Galvani, Ltd. Method and apparatus for electrically forcing cardiac output in an arrhythmia patient
US6017577A (en) * 1995-02-01 2000-01-25 Schneider (Usa) Inc. Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices
US6027742A (en) * 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US5603556A (en) * 1995-11-20 1997-02-18 Technical Services And Marketing, Inc. Rail car load sensor
US6051017A (en) * 1996-02-20 2000-04-18 Advanced Bionics Corporation Implantable microstimulator and systems employing the same
US6174329B1 (en) * 1996-08-22 2001-01-16 Advanced Cardiovascular Systems, Inc. Protective coating for a stent with intermediate radiopaque coating
US6021347A (en) * 1996-12-05 2000-02-01 Herbst; Ewa Electrochemical treatment of malignant tumors
US6013591A (en) * 1997-01-16 2000-01-11 Massachusetts Institute Of Technology Nanocrystalline apatites and composites, prostheses incorporating them, and method for their production
US5858556A (en) * 1997-01-21 1999-01-12 Uti Corporation Multilayer composite tubular structure and method of making
US6025036A (en) * 1997-05-28 2000-02-15 The United States Of America As Represented By The Secretary Of The Navy Method of producing a film coating by matrix assisted pulsed laser deposition
DE19731021A1 (en) * 1997-07-18 1999-01-21 Meyer Joerg In vivo degradable metallic implant
US6174330B1 (en) * 1997-08-01 2001-01-16 Schneider (Usa) Inc Bioabsorbable marker having radiopaque constituents
US6342507B1 (en) * 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
JP4172912B2 (en) * 1997-11-07 2008-10-29 エクスパンダブル・グラフツ・パートナーシツプ Intravascular stent and method for manufacturing the intravascular stent
NO311781B1 (en) * 1997-11-13 2002-01-28 Medinol Ltd Metal multilayer stents
US6241762B1 (en) * 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6984404B1 (en) * 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
WO2000032608A1 (en) * 1998-11-26 2000-06-08 Infineon Technologies Ag Complex compound of an element of sub-group iv
US6170488B1 (en) * 1999-03-24 2001-01-09 The B. F. Goodrich Company Acoustic-based remotely interrogated diagnostic implant device and system
US6503556B2 (en) * 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US6936066B2 (en) * 1999-11-19 2005-08-30 Advanced Bio Prosthetic Surfaces, Ltd. Complaint implantable medical devices and methods of making same
US6458153B1 (en) * 1999-12-31 2002-10-01 Abps Venture One, Ltd. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US20060013850A1 (en) * 1999-12-03 2006-01-19 Domb Abraham J Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom
JP2005503178A (en) * 2000-01-25 2005-02-03 ボストン サイエンティフィック リミテッド Manufacturing medical devices by vapor deposition
EP1132058A1 (en) * 2000-03-06 2001-09-12 Advanced Laser Applications Holding S.A. Intravascular prothesis
US6315708B1 (en) * 2000-03-31 2001-11-13 Cordis Corporation Stent with self-expanding end sections
US6673385B1 (en) * 2000-05-31 2004-01-06 Advanced Cardiovascular Systems, Inc. Methods for polymeric coatings stents
US6395326B1 (en) * 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
AU2001273276A1 (en) * 2000-07-10 2002-01-21 Epion Corporation Improving effectiveness of medical stents by gcib
US6673105B1 (en) * 2001-04-02 2004-01-06 Advanced Cardiovascular Systems, Inc. Metal prosthesis coated with expandable ePTFE
US7056339B2 (en) * 2001-04-20 2006-06-06 The Board Of Trustees Of The Leland Stanford Junior University Drug delivery platform
JP2004529929A (en) * 2001-04-23 2004-09-30 ニュクリスト ファーマシューティカルズ コーポレーション Use of metals for induction of apoptosis and inhibition of matrix metalloproteinases
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7201940B1 (en) * 2001-06-12 2007-04-10 Advanced Cardiovascular Systems, Inc. Method and apparatus for thermal spray processing of medical devices
US20030003127A1 (en) * 2001-06-27 2003-01-02 Ethicon, Inc. Porous ceramic/porous polymer layered scaffolds for the repair and regeneration of tissue
US6585755B2 (en) * 2001-06-29 2003-07-01 Advanced Cardiovascular Polymeric stent suitable for imaging by MRI and fluoroscopy
WO2003070288A2 (en) * 2001-10-12 2003-08-28 Inframat Corporation Coated implants and methods of coating implants
US20030077310A1 (en) * 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US6506972B1 (en) * 2002-01-22 2003-01-14 Nanoset, Llc Magnetically shielded conductor
NZ534682A (en) * 2002-02-15 2006-10-27 Cv Therapeutics Inc Polymer coating for medical devices
EP1348402A1 (en) * 2002-03-29 2003-10-01 Advanced Laser Applications Holding S.A. Intraluminal endoprosthesis, radially expandable, perforated for drug delivery
US20040000540A1 (en) * 2002-05-23 2004-01-01 Soboyejo Winston O. Laser texturing of surfaces for biomedical implants
US7169178B1 (en) * 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US8281737B2 (en) * 2003-03-10 2012-10-09 Boston Scientific Scimed, Inc. Coated medical device and method for manufacturing the same
DE10311729A1 (en) * 2003-03-18 2004-09-30 Schultheiss, Heinz-Peter, Prof. Dr. Endovascular implant with an at least sectionally active coating of ratjadon and / or a ratjadon derivative
CA2524271C (en) * 2003-05-02 2012-09-04 Surmodics, Inc. Controlled release bioactive agent delivery device
US6846323B2 (en) * 2003-05-15 2005-01-25 Advanced Cardiovascular Systems, Inc. Intravascular stent
US20050021127A1 (en) * 2003-07-21 2005-01-27 Kawula Paul John Porous glass fused onto stent for drug retention
US20050021128A1 (en) * 2003-07-24 2005-01-27 Medtronic Vascular, Inc. Compliant, porous, rolled stent
US7682603B2 (en) * 2003-07-25 2010-03-23 The Trustees Of The University Of Pennsylvania Polymersomes incorporating highly emissive probes
US8435287B2 (en) * 2004-03-30 2013-05-07 Toyo Advanced Technologies Co., Ltd. Stent and method for fabricating the same
DK1809349T3 (en) * 2004-07-05 2009-12-07 Ziscoat N V Biocompatible coating for medical devices comprising molecular sieves
US20060009839A1 (en) * 2004-07-12 2006-01-12 Scimed Life Systems, Inc. Composite vascular graft including bioactive agent coating and biodegradable sheath
US7078108B2 (en) * 2004-07-14 2006-07-18 The Regents Of The University Of California Preparation of high-strength nanometer scale twinned coating and foil
US20060015361A1 (en) * 2004-07-16 2006-01-19 Jurgen Sattler Method and system for customer contact reporting
US7269700B2 (en) * 2004-07-26 2007-09-11 Integrated Device Technology, Inc. Status bus accessing only available quadrants during loop mode operation in a multi-queue first-in first-out memory system
US20070003589A1 (en) * 2005-02-17 2007-01-04 Irina Astafieva Coatings for implantable medical devices containing attractants for endothelial cells
WO2006116492A2 (en) * 2005-04-26 2006-11-02 Christodoulos Stefanadis Method and devices for treatment of vulnerable (unstable) and/or stable atherosclerotic plaque by disrupting pathologic vasa vasorum of the atherosclerotic plaque
DE102005031868A1 (en) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Drug depot for parenteral, especially intravascular drug release
US8771343B2 (en) * 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US7651527B2 (en) * 2006-12-15 2010-01-26 Medtronic Vascular, Inc. Bioresorbable stent
US7632305B2 (en) * 2007-07-06 2009-12-15 Boston Scientific Scimed, Inc. Biodegradable connectors
US7942926B2 (en) * 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) * 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
DE102007032686A1 (en) * 2007-07-13 2009-01-15 Biotronik Vi Patent Ag Stent with a coating
US8205317B2 (en) * 2007-07-16 2012-06-26 Medtronic Vascular, Inc. Method of manufacturing a controlled porosity stent
DE102007034019A1 (en) * 2007-07-20 2009-01-22 Biotronik Vi Patent Ag Stent with a coating or filling of a cavity
US20090024209A1 (en) * 2007-07-20 2009-01-22 Medtronic Vascular, Inc. Hypotubes for Intravascular Drug Delivery
DE102007034041A1 (en) * 2007-07-20 2009-01-22 Biotronik Vi Patent Ag Medication depots for medical implants
US20090028785A1 (en) * 2007-07-23 2009-01-29 Boston Scientific Scimed, Inc. Medical devices with coatings for delivery of a therapeutic agent
DE102007034364A1 (en) * 2007-07-24 2009-01-29 Biotronik Vi Patent Ag Degradable metal stent with active ingredient-containing coating
DE102007034363A1 (en) * 2007-07-24 2009-01-29 Biotronik Vi Patent Ag endoprosthesis
US20090030504A1 (en) * 2007-07-27 2009-01-29 Boston Scientific Scimed, Inc. Medical devices comprising porous inorganic fibers for the release of therapeutic agents
US20090030500A1 (en) * 2007-07-27 2009-01-29 Jan Weber Iron Ion Releasing Endoprostheses
US20100008970A1 (en) * 2007-12-14 2010-01-14 Boston Scientific Scimed, Inc. Drug-Eluting Endoprosthesis
US8317857B2 (en) * 2008-01-10 2012-11-27 Telesis Research, Llc Biodegradable self-expanding prosthesis
DE102008040253A1 (en) * 2008-07-08 2010-01-14 Biotronik Vi Patent Ag Implant system with a functional implant made of degradable metal material
DE102008040356A1 (en) * 2008-07-11 2010-01-14 Biotronik Vi Patent Ag Stent with biodegradable stent struts and drug depots
EP2307070B1 (en) * 2008-07-16 2013-03-27 Boston Scientific Scimed, Inc. Medical devices having metal coatings for controlled drug release
JP2011528939A (en) * 2008-07-23 2011-12-01 ボストン サイエンティフィック サイムド，インコーポレイテッド Medical device having an inorganic barrier coating
DE102008040787A1 (en) * 2008-07-28 2010-02-04 Biotronik Vi Patent Ag Biocorrodible implant with a coating containing a hydrogel
DE102008040786A1 (en) * 2008-07-28 2010-02-04 Biotronik Vi Patent Ag Biocorrodible implant with a coating containing a drug-carrying polymer matrix

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309414B1 (en) * 1997-11-04 2001-10-30 Sorin Biomedica Cardio S.P.A. Angioplasty stents
US20030100815A1 (en) * 2001-11-27 2003-05-29 Pearl Technology Holdings, Llc In-stent restenosis detection device
US20060271192A1 (en) * 2005-03-04 2006-11-30 Olsen Raymond E Self Fixing Assembled Bone-Tendon-Bone Graft

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YI ET AL: "Characterization of a bioactive nanotextured surface created by controlled chemical oxidation of titanium", SURFACE SCIENCE, NORTH-HOLLAND PUBLISHING CO, AMSTERDAM, NL, vol. 600, no. 19, 1 October 2006 (2006-10-01), pages 4613 - 4621, XP005676670, ISSN: 0039-6028 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10346512B2 (en) 2011-03-01 2019-07-09 Applaud, Llc Personalized memory compilation for members of a group and collaborative method to build a memory compilation
US9603728B2 (en) 2013-02-15 2017-03-28 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses
US9522220B2 (en) 2013-10-29 2016-12-20 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses
US10518001B2 (en) 2013-10-29 2019-12-31 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses
US10589005B2 (en) 2015-03-11 2020-03-17 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses

Also Published As

Publication number Publication date
US20100004733A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
US20100004733A1 (en) Implants Including Fractal Structures
US20090030500A1 (en) Iron Ion Releasing Endoprostheses
US8216632B2 (en) Endoprosthesis coating
EP2303348B1 (en) Bioerodible endoprosthesis
EP2173393B1 (en) Boron-enhanced shape memory endoprostheses
US20070038289A1 (en) Stent to be placed in vivo
US20070270940A1 (en) Bioabsorbable Magnesium-Reinforced Polymer Stents
US20090287301A1 (en) Coating for medical implants
US20110282428A1 (en) Biodegradable composite stent
CN104870028B (en) Fully absorbable intraluminal device and method of manufacture
WO2010132244A2 (en) Bioerodible endoprosthesis
JP6667758B2 (en) Bioabsorbable stent
US20110160839A1 (en) Endoprosthesis
Patel et al. Current status and future prospects of drug eluting stents for restenosis/Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove
Ernst et al. New generations of drug-eluting stents-A brief review
US8114153B2 (en) Endoprostheses
US20140144001A1 (en) Stent having function elements
Nguyen et al. Biomaterials and stent technology
WO2007119423A1 (en) Substance to be placed in the living body
RU2571685C2 (en) Implanted stent
AU2011265474B2 (en) Temporal intraluminal stent, methods of making and using
Wnek et al. Stents/Benjamin Thierry, Luc Bilodeau, Maryam Tabrizian
PATEL et al. Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09774453

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09774453

Country of ref document: EP

Kind code of ref document: A1